Holen Sie sich die Stockscreener-App
15.08
0.66%
-0.10
Schlusskurs vom Vortag:
$15.18
Offen:
$14.95
24-Stunden-Volumen:
16,634
Relative Volume:
0.36
Marktkapitalisierung:
$2.63B
Einnahmen:
$603.63M
Nettoeinkommen (Verlust:
$468.71M
KGV:
5.6227
EPS:
2.682
Netto-Cashflow:
$-59.92M
1W Leistung:
+0.87%
1M Leistung:
-0.20%
6M Leistung:
+13.38%
1J Leistung:
-10.50%
1-Tages-Spanne:
$14.95
$15.26
1-Wochen-Bereich:
$14.88
$15.36
52-Wochen-Spanne:
$11.51
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Vergleichen Sie HCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
15.08 | 2.61B | 603.63M | 468.71M | -59.92M | 2.682 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-11-24 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-03 | Eingeleitet | Jefferies | Buy |
| 2020-10-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-03-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Eingeleitet | Goldman | Buy |
| 2019-11-19 | Eingeleitet | CLSA | Buy |
| 2019-10-23 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
Alle ansehen
Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten
ABN Amro Investment Solutions Invests $962,000 in HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
HMPL-A251 combines HER2 targeting with precision payload - BioWorld MedTech
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Globe and Mail
Transcript : HUTCHMED Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025, Nov-04-2025 08 - MarketScreener
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025Slideshow (NASDAQ:HCM) 2025-11-04 - Seeking Alpha
Hutchmed Strengthens Position Within FTSE AIM 100 Index Healthcare Sphere - Kalkine Media
Hutchmed takes wraps off expanding oncology pipeline - Sharecast.com
Market news - investments.halifax.co.uk
RCSHutchmed China LtdUpdates from R&D Event - TradingView
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - The Manila Times
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
International companies to host live webcasts at Deutsche - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - Yahoo Finance
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Vanguard Personalized Indexing Management LLC Buys 4,773 Shares of Cleanspark, Inc. $CLSK - Defense World
Vanguard Personalized Indexing Management LLC Boosts Stake in Knowles Corporation $KN - Defense World
Hutchmed upbeat on preclinical data for novel cancer therapy - Sharecast.com
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
HUTCHMED Highlights HMPL-A251 Data Presented at the - GlobeNewswire
Allianz Asset Management GmbH Sells 80,000 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
Will Can Fite Biopharma Ltd Sponsored ADR stock benefit from mergersQuarterly Risk Review & Risk Controlled Stock Alerts - Trung tâm Dự báo KTTV quốc gia
Working capital per share of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Why HUTCHMED (China) Limited (Common Stock) (H7T1) stock is favored by hedge fundsTrade Exit Report & Technical Entry and Exit Alerts - newser.com
Will HUTCHMED (China) Limited (Common Stock) (H7T1) stock deliver stable dividendsPortfolio Update Report & Verified Chart Pattern Signals - newser.com
BOCOMI: Trump's Additional Tariffs on Imported Innovative Drugs May Have Limited Actual Impact on CN Pharmas - AASTOCKS.com
HUTCHMED (NASDAQ:HCM) Shares Gap DownTime to Sell? - MarketBeat
M Stanley: Increased Recognition Pushes Biotech Stocks to Outpace Mkt - AASTOCKS.com
Best Momentum Stock to Buy for August 19th - MSN
National Research Corporation $NRC Shares Sold by Goldman Sachs Group Inc. - Defense World
HUTCHMED (China) Limited Sponsored ADR $HCM Stock Position Raised by Goldman Sachs Group Inc. - Defense World
HUTCHMED (NASDAQ:HCM) Shares Gap UpHere's What Happened - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap Up – Should You Buy? - Defense World
Price action breakdown for HUTCHMED (China) Limited Depositary Receipt2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Top Blockchain Stocks To Follow Now – September 12th - Defense World
HSBC Research Positive on LT Growth of CN Biotech, Favors INNOVENT BIO/ HANSOH PHARMA - AASTOCKS.com
G Sachs Gives ST Risk Analysis for 3 Types of Firms as US Reportedly Planning to Tighten Scrutiny on CN Innovative Drugs Could Pose 'Headline Risks' for CN Pharmas - AASTOCKS.com
CN SASAC Advocates to Accelerate Development of Central SOEs in the Biopharmaceutical Industry, Build National Team in Such Field - AASTOCKS.com
Intraday pattern recognizer results for HUTCHMED (China) Limited Depositary Receipt2025 Biggest Moves & Trade Opportunity Analysis Reports - Newser
Combining machine learning predictions for HUTCHMED (China) Limited Depositary ReceiptQuarterly Market Review & Verified Entry Point Signals - Newser
How moving averages guide HUTCHMED (China) Limited Depositary Receipt trading2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
HUTCHMED Announces Appointment of Acting Chief Executive Officer - GlobeNewswire Inc.
Solventum Corporation $SOLV Shares Sold by Russell Investments Group Ltd. - Defense World
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewswire
Best Momentum Stock To Buy For August 19th - Barchart.com
Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.58%
4.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):